Azenta Inc
Brooks operates two global, market-leading businesses, Life Sciences and Semiconductor Solutions, each with its own distinct area of focus and expertise. The Life Sciences business, to be operated under the new Azenta brand, provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. On September 20, 2021, the Company announced the pending sale to Thomas H. Lee Partners of its Semiconductor Solutions Group business, which provides industry-leading precision vacuum robotics, integrated automation systems and contamination control solutions to the world's leading semiconductor chip makers and equipment manufacturers as well as collaborative robotics and automation capabilities for multi-market applications. Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia.
Generated $1.1 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$24.91
+1.38%GoodMoat Value
$30.79
23.6% undervaluedAzenta Inc (AZTA) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Azenta Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $594.95M. Gross profit (TTM) is $265.31M. EBITDA is $-33.14M. Earnings per share (EPS) is $-1.22. The P/E ratio is -19.71. Market capitalization is $1.14B.
Free cash flow (FCF) is $38.32M. FCF growth rate is -8.90%. EPS growth CAGR is 50.00%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Azenta Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
